101. Lipoprotein turnover and possible remnant accumulation in preeclampsia: Insights from the Freiburg preeclampsia H.E.L.P.-Apheresis Study

Abstract

Introduction Preeclampsia is a potentially life threatening disease occurring in pregnancy. The only causative cure consists in delivery with all the risks for a premature fetus. In preeclampsia, the lipid metabolism is substantially altered and lipid apheresis is being explored as a possible therapeutic approach to prolong preeclamptic pregnancies and allow further maturation of the fetus. In the Freiburg H.E.L.P.-Apheresis Study, 6 early onset preeclamptic patients were treated with H.E.L.P. apheresis. Objective/hypothesis Detailed analysis of apheresis-induced dynamics in serum lipid parameters. Methods 6 early onset preeclamptic patients underwent repeated apheresis treatments (n = 23). We evaluated parameters of the lipoprotein metabolism in 6 preeclamptic patients in detail. Results Reduction of lipoproteins by apheresis was lower than theoretically expected. Lipids reached previous pre-apheresis levels before the next apheresis even though apheresis was repeated within 2.9 ± 1.2 days. Fractional catabolic rates and synthetic rates were found to be substantially elevated, with fractional catabolic rates for ApoB/ LDL-cholesterol being 0.7 ± 0.3/ 0.4 ± 0.2 [day−1] and synthetic rates being 26 ± 8/ 17 ± 8 [mg*kg−1*day−1]. The distribution of LDL-subclasses after apheresis shifted to larger buoyant LDL, while IDL levels remained unaffected. Discussion Apheresis induced changes in lipoprotein profiles point to an underlying remnant removal disease like imbalance in plasma lipid conversion during preeclamptic conditions.